Diabetes Increases Post-Transplant Mortality Risk

Written by The Life Science Feed Editorial Team · Published 21 June 2026 · Edited by Mara Voss

Organ transplantation offers life-saving treatment for end-stage organ disease, yet recipients face significant long-term complications. A critical concern is the development or exacerbation of diabetes, which is associated with adverse outcomes. Understanding and managing dysglycemia in this vulnerable population is essential for improving post-transplant survival and graft longevity.

KEY TAKEAWAYS

- The Pivot: Continuous glucose monitoring (CGM) offers superior detection of perioperative hyperglycemia and glycemic variability compared to traditional methods in transplant recipients.
- The Data: CGM metric thresholds within the first month post-transplant achieved sensitivities above 85% and specificities up to 83% for PTDM risk.1
- The Action: Clinicians should consider CGM for early detection and management of dysglycemia in kidney transplant recipients, as it provides insights that conventional tests like HbA1c may miss.

Kidney transplantation, the most common solid organ transplant, carries a considerable burden of post-transplant diabetes mellitus (PTDM).1 PTDM is linked to increased cardiovascular events, graft dysfunction, and increased mortality.1 Poor perioperative glycemic control and glycemic variability have been associated with acute rejection and reduced graft survival.1

Clinical Significance of Post-Transplant Diabetes Mellitus

PTDM represents a significant complication following solid organ transplantation, impacting patient and graft survival. Its prevalence varies depending on the organ transplanted, immunosuppressive regimen, and patient characteristics, but it consistently contributes to adverse outcomes. The development of PTDM is multifactorial, involving immunosuppressive medications like corticosteroids and calcineurin inhibitors, which can impair insulin secretion and increase insulin resistance. Pre-existing risk factors such as obesity, family history of diabetes, and certain genetic predispositions also play a crucial role. Early identification and aggressive management of PTDM are paramount to mitigate its long-term consequences, which include accelerated atherosclerosis, increased risk of infections, and progressive kidney disease, even in the transplanted organ. The challenge lies in distinguishing PTDM from pre-existing diabetes and in accurately monitoring glycemic status in a population with complex medical needs and often fluctuating glucose levels.

Continuous Glucose Monitoring in Transplant Recipients

Continuous glucose monitoring (CGM) has transformed diabetes management by offering real-time and dynamic insights into glucose variability, addressing limitations of traditional glucose assessment methods.1 A narrative review explored the role of CGM in kidney transplant recipients, particularly its impact on glycemic profiles and its predictive value for PTDM.1 At the time of this review, CGM had not yet been incorporated into standard transplant care

protocols.1

Evidence shows that perioperative CGM outperforms traditional tests in identifying frequent hyperglycemia and glycemic variability in the first weeks after transplantation, enabling enhanced glycemic control and improving the recipient's clinical outcome.1 Studies demonstrate higher glucose variability in kidney-only recipients compared to other organ recipients, and in type 2 diabetes patients compared to those with PTDM.1 CGM-derived metrics outperform conventional glucose measures in predicting PTDM.1 CGM metric thresholds within the first month post-transplant achieved sensitivities above 85% and specificities up to 83% for PTDM risk.1 CGM-guided adjustment of immunosuppressants and steroid dosing have been shown to reduce hyperglycemia and variability.1 Comparative studies indicate that glycosylated hemoglobin A1c correlates poorly with CGM in the early post-transplant period, often misclassifying patients as normoglycemic.1 CGM appears to offer clinically relevant insights for the early detection, prediction, and management of dysglycemia in kidney transplant recipients.1

Methodology and Patient Population Context

The narrative review synthesized findings from various studies investigating CGM use in kidney transplant recipients. These studies typically involved diverse patient populations, including individuals undergoing their first kidney transplant, re-transplants, and those with varying degrees of pre-existing comorbidities. The review focused on the utility of CGM in the perioperative period, specifically within the first few weeks to months post-transplantation, a critical window for PTDM development and glycemic instability. The studies often employed different CGM devices and monitoring durations, ranging from a few days to several weeks, providing a comprehensive picture of glucose trends. The primary outcomes assessed included the ability of CGM to detect hyperglycemia, glycemic variability, and its predictive power for PTDM development. Secondary outcomes often involved the impact of CGM-guided interventions on glycemic control and clinical outcomes such as acute rejection rates and graft function. The narrative review design allowed for a broad exploration of the existing literature, highlighting both the strengths and limitations of current research in this evolving field.

Limitations and Future Directions

Despite the promising findings, the narrative review also highlighted several limitations in the current body of evidence. Many studies were observational, small in scale, and lacked standardized protocols for CGM implementation and data interpretation. The heterogeneity in patient populations, immunosuppressive regimens, and CGM devices across studies made direct comparisons challenging. Furthermore, the long-term impact of CGM-guided management on patient and graft survival requires further investigation through larger, prospective, randomized controlled trials. The cost-effectiveness of routine CGM use in all transplant recipients also needs evaluation. Future research should focus on developing standardized CGM protocols for transplant recipients, establishing clear thresholds for intervention based on CGM metrics, and exploring the integration of CGM data into electronic health records for seamless clinical decision-making. Investigating the role of artificial intelligence and machine learning in analyzing CGM data to predict PTDM and personalize treatment strategies also represents a promising avenue for future research. Ultimately, the goal is to leverage CGM technology to optimize glycemic control, reduce PTDM-related complications, and improve the overall quality of life for kidney transplant recipients.

REFERENCES: 1. Oweidat K, Field BCT, Farmer CK. Continuous glucose monitoring in kidney transplant recipients: a narrative review. BMC Nephrol 2025.

CLINICAL IMPLICATIONS

The evidence supporting continuous glucose monitoring (CGM) in kidney transplant recipients is compelling. The poor correlation of HbA1c with actual glycemic status in the early post-transplant period means that clinicians relying solely on this traditional marker may be missing critical periods of hyperglycemia and variability, directly impacting graft survival and patient mortality. Integrating CGM into perioperative care protocols for kidney transplant recipients seems a logical next step to improve glycemic control and potentially mitigate long-term complications.

For patients, this could mean earlier detection of PTDM risk and more precise management, leading to better clinical outcomes and potentially extending the life of their transplanted organ. The ability to adjust immunosuppressants and steroid dosing based on real-time glucose data offers a personalized approach to care that was previously unavailable. This shift from reactive to proactive glycemic management could significantly enhance patient quality of life post-transplant.

From an industry perspective, the increased adoption of CGM in transplant settings represents an expansion of its utility beyond conventional diabetes management. Device manufacturers should consider developing specific algorithms or features tailored to the unique physiological challenges of transplant recipients, such as interactions with immunosuppressive regimens. Guideline bodies, such as the American Society of Transplantation, should evaluate the current evidence to consider incorporating CGM into their recommendations for post-transplant care, thereby standardizing its use and ensuring equitable access.

EDITORIAL & AI STANDARDS

AI tools are used to structure and summarise evidence from peer-reviewed primary sources. Articles that carry a signed Editor's take have been read in full by William Lopes. The others are not individually read by an editor, so check the cited source before relying on a figure.

REFERENCES

1. 1. Oweidat K, Field BCT, Farmer CK. Continuous glucose monitoring in kidney transplant recipients: a narrative review. BMC Nephrol 2025. doi:10.1186/s12882-025-04691-2

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed